Kura Oncology Q3 net loss $74.1M; progress on ziftomenib Phase 3 trials

Kura Oncology, Inc.

2025-Q3 EPS reported -$2.26 vs consensus -$0.87 ▼ miss (-160.1%)

Net loss of $74.1M in Q3 2025 vs $54.4M in Q3 2024; R&D spend rose to $67.9M.
Collaboration revenue of $20.8M from Kyowa Kirin partnership; no revenue in prior year.
Pro forma cash $609.7M; cash runway into 2027 supports ziftomenib program through KOMET-017 topline.
First patients dosed in KOMET-017 Phase 3 (frontline AML) and FLT3 inhibitor cohort of KOMET-007.
PDUFA target date Nov 30, 2025 for ziftomenib in R/R NPM1-m AML; two oral ASH 2025 abstracts.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.